about
Intestinal epithelial cells in inflammatory bowel diseases.Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effectComplete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection.Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.Antimicrobial stewardship in a Gastroenterology Department: Impact on antimicrobial consumption, antimicrobial resistance and clinical outcome.Update on current applications of proteomic in the study of inflammatory bowel disease.The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.Stress and brain functional changes in patients with Crohn's disease: A functional magnetic resonance imaging study.Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease.Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?Is Early Endoscopy-Based Therapy the Best Strategy to Prevent All Crohn's Disease Postoperative Recurrence?Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.Low molecular weight heparin does not increase bleeding and mortality post endoscopic variceal band ligation in cirrhotic patients.Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study.Fecal detection of Mycobacterium avium paratuberculosis using the IS900 DNA sequence in Crohn's disease and ulcerative colitis patients and healthy subjectsRetention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy“Blindly” ADA Dose Escalation to 80 mg Weekly in Crohnʼs Disease Patients with LORLetter: TNFα inhibitors and prevalence of fatty liver disease in chronic inflammatory diseasesSplenic granulomas in a patient with severe Crohn's disease associated with multiple extraintestinal manifestationsLetter: TNFα blockers and psoriasis: a 'reasonable paradox' - the role of TH-17 cellsBactDNA as an Independent Risk Factor for Short-Term Crohn's Disease RecurrenceOutcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
P50
Q34136264-420B5C39-EEC4-4AAE-B365-1A5C5C8D5FBCQ34416022-BB535A35-3E0C-4430-A377-84B88E195E1AQ36530664-DA194FA5-42CB-4567-AB77-F98C3D0B7C3DQ39007371-7A3C8126-D744-4104-82C5-AA371FD6F08CQ39564891-06535828-1C8F-4916-8990-C8DC8739A4A8Q42406649-7B046D2B-7586-4511-9D60-987A261649B9Q47596377-1BEE5F3F-7352-46BC-A706-85D7250F79B1Q47708577-9E0421DA-6CC9-4E46-A73C-73CCE7E5615AQ48171878-3B303D55-9514-439A-BC08-6BD4E9F51DADQ48178445-8D7CC433-7228-4B39-90B1-5D6BE550F7B4Q49014512-E2EB46B0-A69E-4E77-AFD5-DD15F73E0C09Q49391345-84CA09CC-DF00-4970-8E11-C6607B8439A4Q50146213-D5CAE9E9-8520-4FE5-A2C2-DC979F7C7D41Q51085282-A062D368-6DF3-44C0-9649-6D16C4E57304Q56984269-9C34C71A-A8C0-4A09-838B-55C91C422A57Q58605978-B40B00BF-0ECB-4A0C-ADCA-AC2B0B45F0FBQ58811079-F16858C8-078C-4376-9A26-DB87B10E7D20Q58811080-5D70EB54-FD20-4FBD-B7D6-BB13ED8FAE7EQ83407056-24AEA30E-5CFF-46E3-AED2-6F5E4B0AC860Q87686684-3F69EA60-E484-4B60-8245-968A30A65AE2Q88466800-2F2D85AD-2866-4EA2-B582-E6E02375A323Q94473472-1A3731AB-3CC1-4571-81A9-DF641C304015
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Sartini
@ast
Alessandro Sartini
@en
Alessandro Sartini
@es
Alessandro Sartini
@nl
Alessandro Sartini
@sl
type
label
Alessandro Sartini
@ast
Alessandro Sartini
@en
Alessandro Sartini
@es
Alessandro Sartini
@nl
Alessandro Sartini
@sl
prefLabel
Alessandro Sartini
@ast
Alessandro Sartini
@en
Alessandro Sartini
@es
Alessandro Sartini
@nl
Alessandro Sartini
@sl
P106
P1153
55778145659
P21
P31
P496
0000-0003-1573-6451